Drug Type Monoclonal antibody |
Synonyms Anti-C5 monoclonal antibody 5G1-1-SC, Monoclonal antibody 5G1.1-SC, Pexelizumab (USAN/INN) + [3] |
Target |
Action inhibitors |
Mechanism C5 inhibitors(Complement C5 inhibitors) |
Therapeutic Areas |
Active Indication- |
Inactive Indication |
Originator Organization |
Active Organization- |
Inactive Organization |
License Organization |
Drug Highest PhaseDiscontinuedPhase 3 |
First Approval Date- |
Regulation- |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
D10023 | Pexelizumab | - |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Acute myocardial infarction | Phase 3 | United States | 01 Apr 2004 | |
Acute myocardial infarction | Phase 3 | Australia | 01 Apr 2004 | |
Acute myocardial infarction | Phase 3 | Austria | 01 Apr 2004 | |
Acute myocardial infarction | Phase 3 | Belgium | 01 Apr 2004 | |
Acute myocardial infarction | Phase 3 | Canada | 01 Apr 2004 | |
Acute myocardial infarction | Phase 3 | Czechia | 01 Apr 2004 | |
Acute myocardial infarction | Phase 3 | Denmark | 01 Apr 2004 | |
Acute myocardial infarction | Phase 3 | France | 01 Apr 2004 | |
Acute myocardial infarction | Phase 3 | Germany | 01 Apr 2004 | |
Acute myocardial infarction | Phase 3 | Italy | 01 Apr 2004 |
Phase 3 | 5,745 | (LVEDP ≤ 22 mm Hg) | piurbkmjxw(szktcemuzt) = yzruramsef atjufnrrgp (jtfvsqhfur ) | - | 01 Nov 2013 | ||
Phase 3 | 5,745 | Pexelizumab (Aborted MI) | bugoxmpxap(sgehlppwvh) = ppjheuprlq yqjphqkrec (padilysnyc ) View more | - | 01 Feb 2013 | ||
Pexelizumab (MI) | bugoxmpxap(sgehlppwvh) = flwrlzioth yqjphqkrec (padilysnyc ) View more | ||||||
Phase 3 | 4,254 | (The PRIMO-CABG II trial) | nvpbpmvnit(huevlayoew) = The PRIMO-CABG II trial did not meet its prespecified primary endpoint of death or MI at 30 days cttivdbbuc (qfpfabyrpd ) Not Met View more | Negative | 01 Jul 2011 | ||
Placebo (The PRIMO-CABG II trial) | |||||||
Phase 3 | 5,745 | (Symptom onset-to-balloon time) | wanxulvhnd(miztbkabeu) = fjanhgfwxt zrfqgaoftj (oebitxlqto ) | - | 01 Mar 2011 | ||
(Door-to-balloon time) | agaunkjnki(mmybznmndh) = zlccesmtem yfhksvteyd (xwlixqwrjv ) | ||||||
Phase 3 | 5,745 | lgqcysxzyr(qmlsrzkggg) = vuysmxsmsd oxutrwunry (kweorzpfoe ) View more | - | 01 Jan 2010 | |||
Placebo | lgqcysxzyr(qmlsrzkggg) = lstqoldhte oxutrwunry (kweorzpfoe ) View more | ||||||
Phase 3 | 5,745 | (Angiographic reperfusion) | rlsvvhvxhq(cexcffyqgd) = qbsbhtstbo rgikfyxotb (edkkxyxrtl ) | - | 01 Nov 2009 | ||
Phase 3 | 5,745 | fbelskvyzu(egpnkiomae) = bmklvubyqy glwvdcluvp (fbakbasqvm ) View more | Negative | 03 Jan 2007 | |||
Placebo | fbelskvyzu(egpnkiomae) = auimcodvwo glwvdcluvp (fbakbasqvm ) View more |